Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Mineralocorticoid receptor antagonists and agonists act on the nuclear receptor for aldosterone. The mineralocorticoid receptor (MR) is a ligand-activated transcription factor that controls sodium and potassium handling in the kidney and also acts in heart, vessels and brain. Cloning of human MR in 1987 revealed close structural kinship with the glucocorticoid receptor. MR binds cortisol and aldosterone with similar affinity, and a 1988 study showed that its selectivity in target tissues is set by an enzyme, not by the receptor. Canrenoate potassium is a steroidal antagonist related to spironolactone, whereas finerenone, esaxerenone and apararenone are nonsteroidal antagonists. Deoxycorticosterone and 18-oxocortisol are included as steroid agonists that activate the receptor.
Synonyms: AZD9977
Balcinrenone (AZD9977) is a selective, orally active modulator of the mineralocorticoid receptor (MR). It demonstrates significant biological activity in the context of heart failure and chronic kidney disease research. This compound is primarily utilized in studies investigating MR-related pathways and their implications in cardiovascular and renal health.
Felodipine 3,5-Dimethyl Ester is a dihydropyridine derivative functioning primarily as a mineralocorticoid receptor modulator and a selective inhibitor of the voltage-dependent L-type calcium channel CaV1.2. This compound exhibits significant pharmacological activity by affecting calcium ion flux, which plays a crucial role in cardiovascular and renal physiology. Its applications extend to research in hypertension, heart failure, and other cardiovascular disorders related to calcium channel dysregulation.
